Abstract: A novel coronavirus disease (COVID-19) was identified in Wuhan City, Hubei Province of China by the end of 2019, and then, the disease spread across China and became a global pandemic. Nevertheless, there are no effective treatments or vaccines for COVID-19 until now. In addition to the treatment of patients with COVID-19, the China Medical Treatment Expert Group for COVID-19 is active to study and screen effective antiviral drugs, and has found that chloroquine, an old antimalarial, shows activity against SARS-CoV-2. Then, chloroquine was included in the Guidelines for the Diagnosis and Treatment of COVID-19 in China (version 6) issued by National Health Commission of the People’s Republic of China. Currently, chloroquine phosphate and hydroxychloroquine sulfate, two chloroquine derivatives, are under clinical use. Although these two agents exhibit similar mechanisms of drug actions, there is a difference between these two chemicals in terms of target populations, therapeutic efficacy and adverse reactions. This paper summarizes the currently available data and experiences from clinical treatment for malaria with chloroquine drugs, so as to provide insights into the more rational use of chloroquine agents for the treatment of COVID-19.

Key words: Malaria, Coronavirus disease 2019 (COVID-19), Chloroquine phosphate, Hydroxychloroquine sulfate

摘要： 2019 年底，我国湖北省武汉市出现了新型冠状病毒肺炎疫情，随后在全国扩散并成为全球大流行。由于尚无针对新型冠状病毒的特效治疗药物和疫苗，我国新型冠状病毒感染救治临床专家团队在救治新型冠状病毒感染患者的同时，积极研究和筛选有效抗病毒治疗药物，发现一种古老的抗疟药——氯喹有一定抗新型冠状病毒效果，随后纳入我国新型冠状病毒肺炎诊疗方案。目前，临床应用的是氯喹衍生物磷酸氯喹和硫酸羟氯喹，这两种药物虽药理机制相近，但其治疗对象、疗效和不良反应均存在一定差异。本文拟通过对氯喹类药物已有研究和在疟疾临床治疗中的经验总结，为我国临床专家更科学合理地使用氯喹类药物进行新型冠状病毒肺炎治疗提供参考。 　

关键词: 疟疾, 新型冠状病毒肺炎, 磷酸氯喹, 硫酸羟氯喹